Richard Deluca Sells 12,837 Shares of Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca sold 12,837 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $131.76, for a total transaction of $1,691,403.12. Following the completion of the transaction, the executive vice president owned 121,866 shares of the company’s stock, valued at approximately $16,057,064.16. The trade was a 9.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Merck & Co., Inc. Trading Up 2.0%

NYSE:MRK opened at $135.57 on Friday. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.68. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company’s 50-day simple moving average is $125.25 and its 200 day simple moving average is $119.83. The firm has a market capitalization of $334.49 billion, a P/E ratio of 108.46, a PEG ratio of 5.73 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the firm earned $2.13 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. CICC Research began coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Citigroup assumed coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Argus upped their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $135.50.

Institutional Trading of Merck & Co., Inc.

Several institutional investors have recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the 4th quarter worth about $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. in the 4th quarter worth about $26,000. High Note Wealth LLC lifted its stake in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the 4th quarter valued at about $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.